Jonathan Campbell, Ph.D.
Assistant Professor of Medicine
Dr. Campbell studies glucose-dependent insulinotropic peptide (GIP), an incretin hormone released from the proximal small intestine that stimulates insulin release after a meal.
The field of incretin biology has long focused on the other incretin, glucagon-like peptide-1 (GLP-1), and utilized this hormone as a pharmaceutical target for diabetes and obesity. GIP, however, is less well understood; previous studies demonstrate that GIP resistance and receptor loss is associated with decline in pancreatic beta cell function, as seen in type II diabetes. Dr. Campbell’s laboratory is working to uncover the mechanism and effects of GIP.
Using global GIP receptor knockouts, he has shown that beta cells without GIPR are more sensitive to the other incretin, GLP-1, and maintain the ability to secrete insulin. Dr. Campbell is creating tissue-specific knockout models to describe beta cell defects seen in his transcription factor knockout experiments. His goal is that these experiments may serve as a target for diabetes pharmaceuticals.